McInnes IB - Search Results

1

Rheumatoid arthritis.

Smolen JS, Aletaha D, McInnes IB. Smolen JS, et al. Among authors: mcinnes ib. Lancet. 2016 Oct 22;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3. Lancet. 2016. PMID: 27156434 Free article. Review.

2

Management of rheumatoid arthritis.

McInnes IB, Capell HA. McInnes IB, et al. Scott Med J. 1995 Apr;40(2):35-6. doi: 10.1177/003693309504000201. Scott Med J. 1995. PMID: 7618065 No abstract available.

3

Outcome of second line therapy in rheumatoid arthritis.

Porter DR, McInnes I, Hunter J, Capell HA. Porter DR, et al. Ann Rheum Dis. 1994 Dec;53(12):812-5. doi: 10.1136/ard.53.12.812. Ann Rheum Dis. 1994. PMID: 7864689 Free PMC article. Clinical Trial.

4

The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor.

Crilly A, McInnes IB, Capell HA, Madhok R. Crilly A, et al. Among authors: mcinnes ib. Scand J Rheumatol. 1994;23(2):87-91. doi: 10.3109/03009749409103034. Scand J Rheumatol. 1994. PMID: 8165444

5

The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis.

McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, Sturrock RD, Wilkinson PC, Liew FY. McInnes IB, et al. Nat Med. 1996 Feb;2(2):175-82. doi: 10.1038/nm0296-175. Nat Med. 1996. PMID: 8574962

6

Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis.

McInnes IB, Porter D, Murphy EA, Thomson EA, Madhok R, Hunter JA, Pullar T, Capell HA. McInnes IB, et al. Ann Rheum Dis. 1996 May;55(5):328-30. doi: 10.1136/ard.55.5.328. Ann Rheum Dis. 1996. PMID: 8660109 Free PMC article. Clinical Trial.

7

Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients.

McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, Kinninmonth A, Weidner J, Mumford R, Liew FY. McInnes IB, et al. J Exp Med. 1996 Oct 1;184(4):1519-24. doi: 10.1084/jem.184.4.1519. J Exp Med. 1996. PMID: 8879223 Free PMC article.

8

Is rheumatoid arthritis becoming a milder disease? Or are we starting second-line therapy in patients with milder disease?

Porter DR, Capell HA, McInnes I, Munro R, Madhok R, Hunter JA, Thomson EA. Porter DR, et al. Br J Rheumatol. 1996 Dec;35(12):1305-8. doi: 10.1093/rheumatology/35.12.1305. Br J Rheumatol. 1996. PMID: 9010061

9

Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis.

McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. McInnes IB, et al. Nat Med. 1997 Feb;3(2):189-95. doi: 10.1038/nm0297-189. Nat Med. 1997. PMID: 9018238

10

Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology.

Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY. Ruchatz H, et al. Among authors: mcinnes ib. J Immunol. 1998 Jun 1;160(11):5654-60. J Immunol. 1998. PMID: 9605172 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results